Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2016

View Archived Issues

Plasma, urine and ligament tissue metabolites as potential biomarkers of ankylosing spondylitis

New PDE4 inhibitor blocks proinflammatory effects in plasma and CNS

MabVax Therapeutics reports progress in MVT-5873 and MVT-2163 programs

Resunab demonstrates clinical benefit in phase II trial in systemic sclerosis

Novel optimized mouse model of cyclophosphamide-induced bone marrow suppression

RXFP1 agonist ML-290 as a potential treatment for acute myocardial infarction

Full results of EUCLID trial of ticagrelor in peripheral artery disease trial divulged

Seegene and Institut Catala d'Oncologia collaborate on cancer diagnostics

CellMax-DNA Genetic Cancer Risk Test available in India

FDA gives fast track designation to Centrexion Therapeutics' CNTX-4975 for Morton's neuroma

Bristol-Myers Squibb and Enterome establish microbiome-focused immuno-oncology collaboration

AstraZeneca reviews highlights of third quarter 2016

OSE Immunotherapeutics and Selexis enter cancer immunotherapy, autoimmune disease collaboration

Otsuka announces pipeline developments of third quarter 2016

Aurora Diagnostics selected to provide Ventana PD-L1 Assay in U.S.

BLA submission for bevacizumab biosimilar ABP-215

Arena Pharmaceuticals patents 5-HT2C receptor agonists

Clearside Biomedical enrolls first patient in HULK study

ImmunoMet Therapeutics discloses OXPHOX inhibitors

Rhizen initiates phase I/IIa study of RP-3128 for asthma

H. Lundbeck describes PDE1 inhibitors

Bayer Pharma develops t-PA inhibitors

Medshine Discovery presents EGFR inhibitors

Modus Therapeutics gives update on phase II sevuparin study in sickle cell disease

ACADIA Pharmaceuticals begins phase II ADVANCE trial of pimavanserin

Albireo Pharma's A-4250 accepted into PRIME program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...